Jared Whitlock is a Features Editor at Endpoints News. He focuses on medicine and healthcare, including medical specialties, diagnostics, healthcare technology, and the intersection of science with law and legislation. He has been featured in Endpoints News and was a Fall 2021 fellow at KSJ at MIT.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jared Whitlock's coverage primarily revolves around legal and compliance issues within the healthcare, pharmaceutical, and biotechnology industries. He also focuses on private sector announcements and government announcements related to these sectors.
To effectively reach out to Jared, experts in legal matters related to healthcare and biotechnology would be valuable sources for commentary or analysis of industry-specific regulations. Professionals with insights into corporate governance, M&A activities, executive appointments/departures within pharmaceutical or biotech companies could also provide relevant perspectives.
As his geographic focus is not specified but given the nature of his articles which often involve US-based companies such as Illumina, focusing on developments within the United States in relation to regulatory changes or specific company actions may be particularly relevant when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Pleno has raised an additional $25 million in private funding to advance its tests that detect biological targets for drug research and diagnostics.
President-elect Donald Trump's two picks for the Federal Trade Commission are likely to usher in more life sciences deals while maintaining the agency's pressure on …
Last March, I received a flurry of texts and emails from readers. It was one of the strongest reactions I've ever gotten to an article …
By: Jared Whitlock
Tracer Biotechnologies has raised a $10 million Series A round to advance its technology that's designed to monitor circulating tumor DNA in cancer patients over …
By: Jared Whitlock
GemmaBio, a company founded by gene therapy pioneer Jim Wilson, has raised $34 million in seed funding to try and resuscitate the floundering gene therapy field.
By: Jared Whitlock
An affiliate of Deerfield Management Company will acquire Singular Genomics Systems, ending a months-long competition between two suitors that bid up the price of the …
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers. Shortly after, they did what many researchers ...
(833) 317-6278 
